- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07912294
Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction
Clinical Evaluation of Hyper-Diluted Calcium Hydroxylapatite Versus Hyaluronic Acid in the Reconstruction of Interdental Papilla Deficiencies: A Split-Mouth Study
This study aims to compare two injectable materials, calcium hydroxylapatite (Radiesse®) and hyaluronic acid, for treating gaps between the teeth caused by loss of gum tissue. These gaps, commonly known as "black triangles," can affect the appearance of a person's smile and may cause food to become trapped between the teeth.
Hyaluronic acid has been used to improve the appearance of these gaps, but its effects may not last for a long time. Calcium hydroxylapatite is another injectable material that may help the body produce collagen, a natural protein that supports gum tissue. This study will investigate whether calcium hydroxylapatite can provide better or longer-lasting results compared with hyaluronic acid.
The study will take place at the Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia. Approximately 20 healthy adults who have two similar gaps between their front teeth will be invited to participate.
Each participant will receive both treatments. One gap will be treated with diluted calcium hydroxylapatite, while the other will be treated with hyaluronic acid. The treatment for each site will be selected randomly to ensure a fair comparison. Each site will receive one injection.
Participants will be examined before treatment and again after 3 weeks, 3 months, and 6 months to assess the results.
During these visits, photographs and clinical measurements will be taken to evaluate changes in the size of the gaps and the amount of gum tissue between the teeth. Participants will also be asked about their satisfaction with the appearance of their gums, any discomfort experienced during treatment, and whether they have noticed an improvement in their smile. Any side effects or complications will also be recorded.
The researchers will compare how well the two materials improve the appearance of the gaps and how long the improvements last.
Participation will be voluntary, and all participants will receive information about the study before signing a consent form. Their personal information will be kept confidential, and they may withdraw from the study at any time without affecting their dental care.
The main goal of this study is to identify whether diluted calcium hydroxylapatite or hyaluronic acid provides better and longer-lasting improvement in the appearance of gaps between the teeth. The findings may help dentists choose more effective, minimally invasive treatments for patients with missing gum tissue between their teeth.
Panoramica dello studio
Stato
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18 years or older.
- Systemically healthy individuals with no history of chronic systemic diseases.
- Patients with a healthy periodontium.
- Patients presenting with two comparable interdental papilla deficiencies in the esthetic zone.
- Patients with Class I interdental papilla loss according to the Nordland and Tarnow classification.
Exclusion Criteria:
- Patients with chronic systemic diseases.
- Pregnant or lactating women.
- Current smokers.
- Children and adolescents under 18 years of age.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Hyper-Diluted Calcium Hydroxylapatite (Radiesse®)
Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyper-diluted calcium hydroxylapatite (Radiesse®), prepared at a 1:2 dilution ratio using saline and lidocaine. The intervention aims to improve interdental papillary fill and stimulate collagen production, potentially providing longer-lasting tissue improvement. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment. |
Hyper-diluted calcium hydroxylapatite (Radiesse®) will be used for the treatment of Class I interdental papilla deficiencies. The material will be prepared at a 1:2 dilution ratio using saline and lidocaine, mixed through a Luer-lock syringe connection. Each randomly assigned interdental site will receive a single injection. The treatment aims to stimulate collagen production, improve interdental papillary fill, and enhance soft tissue volume and stability. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. |
|
Comparatore attivo: Hyaluronic Acid (HA)
Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyaluronic acid (HA). The intervention aims to improve interdental papillary fill by increasing soft tissue volume and reducing the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment. |
Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Reduction in Black Triangle Area
Lasso di tempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in the area of the open gingival embrasure (black triangle) following treatment, measured in square millimeters (mm²) using standardized calibrated digital clinical photographs. The reduction in black triangle area will be compared between the calcium hydroxylapatite and hyaluronic acid treatment sites to evaluate the effectiveness of papillary reconstruction. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
|
Change in Interdental Papilla Height
Lasso di tempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in interdental papilla height (mm) from baseline following treatment with hyper-diluted calcium hydroxylapatite or hyaluronic acid. Papillary height will be measured using standardized digital clinical photographs calibrated with a UNC-15 periodontal probe and analyzed using image-analysis software (ImageJ). The distance from the papilla tip to a reference line connecting the adjacent gingival margins will be measured. Changes in papillary height will be compared between the two treatment sites. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Interdental Papilla Thickness
Lasso di tempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in interdental papilla thickness (mm) following treatment with calcium hydroxylapatite or hyaluronic acid. Tissue thickness will be assessed using a calibrated endodontic file fitted with a silicone stopper at a standardized reference point. Changes in tissue thickness will be compared between treatment sites to estimate improvements in papillary tissue bulk. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
|
Patient Satisfaction With Esthetic Outcomes
Lasso di tempo: 3 weeks, 3 months, and 6 months after treatment.
|
Patient satisfaction with the appearance of the treated interdental papilla will be assessed using a Visual Analog Scale (VAS). Participants will evaluate their satisfaction with the esthetic improvement achieved following each treatment. Satisfaction scores will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Global Aesthetic Improvement Scale (GAIS)
Lasso di tempo: 3 weeks, 3 months, and 6 months after treatment.
|
Esthetic improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS), a five-point scale ranging from "worse" to "very much improved." Both participants and investigators will evaluate the improvement in interdental papilla appearance compared with baseline. Scores will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Stability of Interdental Papillary Fill
Lasso di tempo: 3 weeks, 3 months, and 6 months after treatment.
|
The stability of interdental papillary reconstruction will be evaluated by comparing changes in papilla height and black triangle dimensions across follow-up visits. The maintenance of treatment-related improvements at 6 months will be assessed to compare the durability of calcium hydroxylapatite and hyaluronic acid injections. |
3 weeks, 3 months, and 6 months after treatment.
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient Satisfaction Questionnaire (PSQ-18)
Lasso di tempo: 3 weeks, 3 months, and 6 months after treatment.
|
Patient-reported satisfaction will be evaluated using the Patient Satisfaction Questionnaire Short Form (PSQ-18), consisting of 18 items. The questionnaire will assess satisfaction with treatment, comfort, perceived improvement, and overall treatment experience. Responses will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Adverse Events and Complications
Lasso di tempo: From the injection procedure through the 6-month follow-up period.
|
Any adverse effects or complications associated with calcium hydroxylapatite or hyaluronic acid injections will be recorded and compared between the treatment sites. The number and nature of reported complications will be documented to evaluate the safety of both interventions. |
From the injection procedure through the 6-month follow-up period.
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 132-09-26
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .